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Edited by Lukas HuberAbstract Phosphodiesterases (PDEs) are enzymes that degrade
intracellular cAMP. In the present study, 3-isobutyl-1-methyl-
xanthine (IBMX) and pentoxifylline, PDE inhibitors, induced
osteoclast formation in cocultures of mouse bone marrow cells
and calvarial osteoblasts. These inhibitors induced the expression
of the osteoclast diﬀerentiation factor, TNF-related activation
induced cytokine (TRANCE, identical to RANKL, ODF, and
OPGL), in calvarial osteoblasts. IBMX induced phosphorylation
of extracellular signal-regulated kinase (ERK) and p38 mitogen-
activated protein kinase (MAPK) in osteoblasts. Induction of
TRANCE expression by IBMX was partially suppressed by
the inhibitors of protein kinase A (PKA), ERK, and p38 MAPK,
suggesting that activation of ERK and p38 MAPK, as well as
PKA, is involved in TRANCE expression by IBMX. Osteoblasts
expressed PDE4, a PDE subtype, and rolipram, a selective
inhibitor of PDE4, induced TRANCE expression. These results
suggest that PDE4 is a key regulator of TRANCE expression in
osteoblasts, which in turn controls osteoclast formation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Osteoclasts are multinucleated giant cells responsible for
bone resorption [1]. Osteoblasts, as well as stromal cells, are
essentially required for osteoclastogenesis through cell–cell
interactions with osteoclast precursors of monocyte/macro-
phage lineage [2,3]. In cocultures of mouse bone marrow cells
and calvarial osteoblasts, osteoclasts are formed in response toAbbreviations: PDE, phosphodiesterase; TRANCE, TNF-related acti-
vation-induced cytokine; OPG, osteoprotegerin; PTH, parathyroid
hormone; IBMX, 3-isobutyl-1-methylxanthine; PKA, protein kinase
A; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated
protein kinase
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doi:10.1016/j.febslet.2004.12.066several factors, such as 1,25-dihydroxyvitamin D3
[1,25(OH)2D3], parathyroid hormone (PTH), interleukin
(IL)-6 plus soluble IL-6 receptor, prostaglandin E2 (PGE2),
and calcium [2–4]. Those factors induce the expression of
TNF-related activation-induced cytokine (TRANCE, also
known as RANKL, ODF, or OPGL) in osteoblasts, which
triggers osteoclast diﬀerentiation [5–8]. Osteoblasts also pro-
duce osteoprotegerin (OPG), a decoy receptor for TRANCE,
to inhibit osteoclast formation [9].
Cyclic adenosine monophosphate (cAMP) is a secondary
messenger in intracellular signaling cascades and elevation of
intracellular cAMP levels activates protein kinase A (PKA)
and controls gene expression and cell function [10,11]. This
pathway is known to induce TRANCE expression in osteo-
blasts following stimulation with PTH and PGE2 [12–14].
Intracellular cAMP is generated by adenylate cyclase from
adenosine triphosphate (ATP) as a substrate, whereas
cAMP-speciﬁc phosphodiesterases (PDEs) degrade cAMP by
hydrolysis [10,11]. Thus, intracellular cAMP gradients are gov-
erned by a balance between its generation by adenylate cyclase
and degradation by PDEs.
The PDE family consists of 11 isozymes, PDE1 to 11, and
those involved in the degradation of cAMP are PDE1, 2, 3,
4, 7, 8, 10, and 11, with some PDE isozymes further classiﬁed
into subtypes [11]. Various low molecular weight inhibitors of
PDEs have been used as tools to study their biological roles in
bone metabolism [15–17]. Pentoxifylline and 3-isobutyl-1-
methylxanthine (IBMX) are PDE inhibitors that inhibit all
members of the PDE family, and induce an elevation of intra-
cellular cAMP levels by inhibiting cAMP hydrolysis [11]. It has
been reported that pentoxifylline and rolipram, a selective
PDE4 inhibitor, increase systemic bone-mass in mice [15].
Other PDE4 inhibitors have also been reported to show a ther-
apeutic eﬀect against bone loss in some animal osteopenia
models [16,17]. Therefore, PDE inhibitors are considered to
be promising candidates for anti-osteoporosis drug therapies,
however, their eﬀects on osteoclastogenesis have not been fully
elucidated.
In the present study, the eﬀects of PDE inhibitors on osteo-
clast formation were examined using a mouse coculture
system. We found that IBMX, pentoxifylline, and the PDE4-
selective inhibitor, rolipram, strongly induced osteoclast
formation in the cocultures. Further, TRANCE mRNA and
protein expression levels were elevated by IBMX and rolipram
in calvarial osteoblasts. Our results also suggested thatblished by Elsevier B.V. All rights reserved.
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only by PKA, but also by extracellular signal-regulated kinase
(ERK) and p38 mitogen-activated protein kinase (MAPK).
Thus, PDE4 is considered to act as a key regulator of
TRANCE expression in osteoblasts.2. Materials and methods
2.1. Reagents
IBMX and toluidine blue were purchased from Wako Pure Chem-
ical Industries Ltd. (Tokyo, Japan). PTH (human, 1-34) was pur-
chased from PEPTIDE Institute, Inc. (Osaka, Japan). PD98059
and SB203580 were obtained from Calbiochem (San Diego, CA,
USA). Antibodies against ERK, phospho-ERK, p38 and phospho-
p38 were purchased from Cell Signaling Technology (Beverly,
MA, USA). All other reagents were from Sigma–Aldrich (St. Louis,
MO, USA).
2.2. Cells and culture system
Primary calvarial osteoblasts were obtained from the calvariae of
neonatal ddY mice (Japan SLC Inc., Shizuoka, Japan) using 0.1% col-
lagenase and 0.2% dispase [18]. Bone marrow cells were obtained from
the long bones of 4- to 6-week-old ddY male mice. UAMS-32 cells
were kindly provided by Dr. Charles A. OBrien (University of Arkan-
sas for Medical Sciences, USA). To examine osteoclast formation,
mouse bone marrow cells (1 · 105 cells) were cocultured with calvarial
osteoblasts (5 · 103 cells), or UAMS-32 cells (5 · 103 cells) in the pres-Fig. 1. Eﬀects of PDE inhibitors on osteoclast formation. (A and B) Dose-de
cocultures. Mouse bone marrow cells and calvarial osteoblasts were cocultu
pentoxifylline (B) for 6 days. Cells were then ﬁxed and stained for TRAP. TR
expressed as means + S.D. of triplicate cultures. (C) Photographs of cocultu
cocultured with (+) or without () 50 lM of IBMX for 6 days. Cells were ﬁxed
pits were stained with toluidine blue after removing the cells and appear as d
mRNA in cocultured cells. Bone marrow cells and calvarial osteoblasts were
RNA was then isolated from the cells and cDNA templates prepared with
determined by RT-PCR using speciﬁc primers designed for each gene. Bar =ence or absence of various concentrations of PDE inhibitors or
1,25(OH)2D3 (10 nM) in 96-well culture plates (CORNING, MA,
USA). After 6 days of culture, cells were ﬁxed and stained for tar-
trate-resistant acid phosphatase (TRAP), a marker enzyme of osteo-
clasts, as described previously [18].
2.3. Pit formation assay
Mouse bone marrow cells (1 · 105 cells) and calvarial osteoblasts
(5 · 103 cells) were cocultured in the presence or absence of IBMX
(50 lM) on dentine slices (0.3 mm thick, 4 mm in diameter) placed in
48-well culture plates for 6 days, as described previously [18]. The slices
were then recovered and stained with toluidine blue to visualize resorp-
tion pits.
2.4. Northern-blot analysis
Calvarial osteoblasts in 60-mm diameter dishes were cultured with
agents for the indicated periods and then subjected to total RNA
extraction using Trizol reagent (Invitrogen, CA, USA) according to
the manufacturers protocols. Total RNA (20 lg) was electrophoresed
on 1.2% agarose–formaldehyde gels, transferred to nylon membrane
ﬁlters (Hybond N+, Amersham Biosciences, Buckinghamshire, UK),
and hybridized with 32P-labeled cDNA probes. After the ﬁnal wash,
the membranes were exposed to X-ray ﬁlm (BioMax, Kodak, NY,
USA) at 70 C.
2.5. Flow cytometry analysis
Osteoblasts treated with or without IBMX (50 lM) for 24 h were
stained with Fc-conjugated soluble TRANCE receptor (RANK)
(kindly provided by Prof. Yongwon Choi, University of Pennsylvania,pendent eﬀects of IBMX and pentoxifylline on osteoclast formation in
red in the presence of the indicated concentrations of IBMX (A) or
AP-positive (+) multinucleated cells (MNCs) were counted. Data are
res (upper panels) and dentin slices (lower panels), on which cells were
and stained for TRAP, which appear as dark-stained cells. Resorption
ark dots. (D) Expression of calcitonin receptor (CTR) and cathepsin K
cocultured for 6 days with (+) or without () 50 lM of IBMX. Total
(+) or without () reverse transcriptase (RT). mRNA expression was
200 lm.
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Pharmingen, San Diego, CA, USA). The stained cells were analyzed
by ﬂow cytometry.
2.6. RT-PCR analysis
Total RNA (1 lg) was reverse-transcribed using Superscript II
(Invitrogen, CA, USA) according to the manufacturers protocols. Ali-
quots of the obtained cDNA pool were subjected to PCR ampliﬁca-
tion with Go Taq DNA polymerase (Promega Co., WI, USA).
Primers for mouse PDE4s, TRANCE, and GAPDH used in this study
are as follows: PDE4A, 5 0-ggaactcacacacctgtcg-30 (forward), 5 0-
gttcttgtgctaagaggtcc-3 0(reverse); PDE4B, 5 0-tggaaatcctggctgccat-3 0
(forward), 5 0-tccacagaagctgtgtgct-3 0 (reverse); PDE4C, 5 0-tggtatcagag-
taggattcc-3 0 (forward), 5 0-ctctgtgtaaaccttggctg-30 (reverse); PDE4D,
5 0-cggaactcgctctgatgt-30 (forward), 5 0-acagaggcgttgtgcttg-3 0 (reverse);
TRANCE, 5 0-ccagccatttgcacacctc-30 (forward), 5 0-agcagggaagggttgg-
aca-3 0 (reverse); calcitonin receptor (CTR), 5 0-tttcaagaaccttagctgcca-
gag-3 0 (forward), 5 0-caaggcacggacaatgttgagaag-3 0 (reverse); cathepsin
K, 5 0-cttccaatacgtgcagcaga-30 (forward), 5 0-acgcaccaatatcttgcacc-30
(reverse); and GAPDH, 5 0-gaaggtcggtgtgaacggatttggc-3 0 (forward),
5 0-catgtaggccatgaggtccaccac-3 0 (reverse). The PCR program was as
follows: 32 (all mouse PDE4s, TRANCE, CTR, and cathepsin K) or
28 (GAPDH) cycles, after an initial denaturation step at 94 C for
3 min, then denaturation at 94 C for 30 s, annealing at 58 C for
45 s, and extension at 72 C for 60 s, with a ﬁnal extension at 72 C
for 10 min.
2.7. Immunoblot analysis
Total cell lysates were isolated, separated by SDS–PAGE, and trans-
ferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA).
The membranes were blocked with 5% non-fat-milk in TBS-T
(150 mM NaCl, 20 mM Tris, pH 7.4, and 0.1% Tween 20), and then
immunostained with anti-phospho p38 (1:1000), anti-phospho ERK
(1:1000), anti-p38 (1:1000) or with anti-ERK antibody (1:1000) fol-
lowed by secondary horseradish peroxidase-conjugated antibody
(1:5000). The membranes were developed using an enhanced chemilu-
minescence detection kit (Amersham Biosciences).Fig. 2. Requirement of TRANCE for osteoclast formation induced by
IBMX. (A) Mouse bone marrow cells and calvarial osteoblasts were
cocultured with (+) or without () 50 lM of IBMX in the presence (+)
or absence () of OPG (100 lg/ml) for 6 days. Cells were then ﬁxed
and stained for TRAP. Data are expressed as means + S.D. of
triplicate cultures. (B) Calvarial osteoblasts were treated with indicated
concentrations of IBMX for 3 h. Total RNA was then extracted from
the osteoblasts and the expression of TRANCE mRNA was examined
by Northern-blot analysis. (C) Osteoblasts were treated with (+) or
without () IBMX (50 lM) for 24 h. Then, cells were harvested and
stained with Fc-conjugated soluble TRANCE receptor (RANK) which
binds to TRANCE followed by phycoerythrin-conjugated anti-IgG
antibody. The stained cells were analyzed by ﬂow cytometry.3. Results
3.1. IBMX stimulates osteoclast formation in mouse coculture
system
We ﬁrst examined the eﬀects of the PDE inhibitors, IBMX
and pentoxifylline, on osteoclast formation using cocultures
of mouse bone marrow cells and calvarial osteoblasts. Each
inhibitor induced TRAP-positive multinucleated cell (MNC)
formation in a dose-dependent manner (Fig. 1A–C). The
mRNA expression levels of CTR and cathepsin K, osteoclast
markers, were increased in the cultures treated with IBMX
(Fig. 1D). When the cells were cocultured in the presence of
IBMX (50 lM) on dentine slices, resorption pits were formed
(Fig. 1C). These results indicate that both IBMX and pentox-
ifylline strongly induce osteoclasts in a mouse coculture sys-
tem.
3.2. Induction of TRANCE expression in calvarial osteoblasts is
involved in osteoclast formation
Osteoclast formation induced by IBMX was completely
inhibited by addition of OPG, a decoy receptor for
TRANCE (Fig. 2A). Furthermore, addition of soluble
TRANCE receptor (RANK) also inhibited osteoclast forma-
tion induced by IBMX (data not shown). These data suggest
that TRANCE is involved in the osteoclast formation in-
duced by IBMX. To determine whether IBMX induces
TRANCE expression, calvarial osteoblasts were treated with
various concentrations of IBMX for 3 h. IBMX elevated
intracellular cAMP levels in osteoblasts within 3 h (datanot shown). IBMX dose-dependently stimulated TRANCE
mRNA expression in calvarial osteoblasts, with the maxi-
mum eﬀect seen at 100 lM (Fig. 2B). In agreement with
this, analysis of osteoblastic cell surface by ﬂow cytometry
revealed that TRANCE expression is upregulated in protein
level after IBMX treatment (Fig. 2C).
3.3. Inhibitors of PKA, ERK and p38 MAPK suppress
TRANCE expression induced by IBMX
To identify the signaling pathways used by IBMX to in-
duce TRANCE expression, the roles of the PKA, ERK,
and p38 MAPK signaling cascades in TRANCE expression
Fig. 3. Eﬀects of H89, PD98059, and SB203580 (inhibitors of PKA, ERK, and p38 MAPK, respectively) on TRANCE mRNA expression (A, C) and
intracellular signal transduction (B) in osteoblasts. (A and C) Calvarial osteoblasts were preincubated in the absence or presence of 30 lM of H89,
50 lM of PD98059, or 50 lM of SB203580 for 30 min, and then treated with (+) or without () 50 lM of IBMX (A) or 100 nM PTH (C) for 3 h.
Total RNA was extracted from the cells and the expressions of TRANCE and GAPDH mRNA were examined by Northern-blot analysis. (B)
Osteoblasts were treated with IBMX (50 lM) for indicated times. Then, cell lysates were harvested, separated by SDS–PAGE, and transferred onto
PVDF membranes. Phospho-ERK, ERK, phospho-p38 MAPK, and p38 MAPK were detected by immunoblotting using speciﬁc antibodies.
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pretreatment of calvarial osteoblasts with a PKA inhibitor,
H89, decreased TRANCE mRNA expression levels induced
by IBMX (Fig. 3A). Interestingly, a MAPK/ERK kinase
(MEK) inhibitor, PD98059, and a p38 MAPK inhibitor,
SB203580, also decreased TRANCE mRNA expression lev-
els induced by IBMX (Fig. 3A). PD98059 and SB203580,
but not H89 alone slightly decreased endogenous TRANCE
mRNA expression levels (Fig. 3A). Immunoblot analysis
using speciﬁc antibodies against phospho-ERK and phos-
pho-p38 MAPK indicated that IBMX induced the activation
of ERK and p38 MAPK pathways in osteoblasts (Fig. 3B).
These results suggest that IBMX regulates TRANCE expres-
sion in osteoblasts via activation of the ERK and p38
MAPK signaling pathways, as well as PKA.
Since PTH is known to stimulate TRANCE mRNA
expression via cAMP accumulation [12,14], we examined
the eﬀects of PD98059 and SB203580 on TRANCE mRNA
expression induced by PTH. These inhibitors also decreased
the expression levels of TRANCE mRNA induced by PTH
(Fig. 3C), suggesting that ERK and p38 MAPK signaling
pathways are involved in PTH-induced TRANCE expres-
sion.3.4. PDE4 is a key regulator of TRANCE expression in
calvarial osteoblasts
To determine the PDE isozymes responsible for TRANCE
expression in calvarial osteoblasts, eﬀects of various isozyme-
selective PDE inhibitors on osteoclast formation and
TRANCE mRNA expression in calvarial osteoblasts were
examined. A PDE4 selective inhibitor, rolipram, dose-depen-
dently induced osteoclast formation and TRANCE mRNA
expression in calvarial osteoblasts (Fig. 4A–C). Vinpocetine,
EHNA, milrinone, dipyridamole, and zaprinast (selective
inhibitors of PDE1, PDE2, PDE3, PDE5 and 8, PDE5 and
9, respectively) did not induce osteoclast formation or
TRANCE mRNA expression in calvarial osteoblasts as
strongly as IBMX and rolipram (Fig. 4A and C). Similar to
the results by IBMX, H89, PD98059, and SB203580 decreased
the TRANCE mRNA expression levels induced by rolipram
(Fig. 4D). These results suggest that TRANCE regulation in
calvarial osteoblasts is attributable to PDE4.
3.5. PDEs regulate TRANCE expression in cells of osteoblastic
lineage
Based on the results shown above, we compared the expres-
sion patterns of PDE4 subtypes in calvarial osteoblasts and the
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osteoblasts, as well as UAMS-32 cells, expressed PDE4A, B,
and 4D, however, not 4C (Fig. 5A). Both calvarial osteoblasts
and UAMS-32 cells supported osteoclast formation, and in-
duced TRANCE mRNA expression in response to IBMX
and 1,25(OH)2D3, an activator of vitamin D receptor-medi-
ated pathway independently of PKA and MAPK (Fig. 5B
and C). These results suggest that not only vitamin D receptor
but also PDEs regulate TRANCE expression in cells of osteo-
blastic lineage.4. Discussion
In the present study, we demonstrated that PDE inhibitors
induce osteoclast formation by inducing TRANCE expression
in calvarial osteoblasts and UAMS-32 cells, suggesting that
PDEs are the key molecules that negatively regulate TRANCE
expression by degrading cAMP. Our results also suggested that
PDE4 mainly regulates cAMP levels and TRANCE expression
in osteoblasts.
In contrast to our results, previous reports have shown the
anabolic eﬀects of PDE inhibitors in vivo [15–17]. Kinoshita
et al. [15] have reported that pentoxifylline and rolipram in-
creased bone mass in animals that were given those drugs in
daily injections. Interestingly, PTH as well as PDE inhibitors
induce osteoclast formation in a mouse coculture system.
However, injections of PTH to animals once daily produce
a net anabolic eﬀect in vivo [14,19]. Furthermore, continu-
ous exposure to PTH leads to a coupled increase in bone
formation and bone resorption, with a net loss of bone mass
[19]. Therefore, PDE inhibitors may induce bone loss if the
animals are administrated continuously. Additional analysis
of PDE inhibitor-administrated animals under various con-
ditions is necessary to understand the eﬀects of PDEs on
bone metabolism.
Elevated intracellular cAMP mainly activates PKA and
this pathway has been implicated in TRANCE-mediated
osteoclast formation [12–14]. In agreement with this, our
experiments showed that the PKA inhibitor reduced the
TRANCE mRNA expression induced by IBMX. Recently,
Rawadi et al. [20] reported that ERK1/2 and p38 MAPK
are activated by pentoxifylline to promote the diﬀerentiation
of osteoblasts. Indeed, our results showed that IBMX acti-
vated ERK and p38 MAPK pathways, and the ERK inhib-
itor, PD98059, and p38 MAPK inhibitor, SB203580, reduced
TRANCE mRNA expression induced by IBMX and roli-
pram. Furthermore, these MAPK inhibitors partially sup-
pressed PTH-induced elevation of TRANCE expression as
well. These results suggest that an alternative signaling path-
way contributes to TRANCE expression via ERK and p38
MAPK activation following the cAMP elevation in osteo-
blasts. Further study will elucidate the precise relationships
between PKA and MAPK.
In the present coculture system, only the PDE4 inhibitor
rolipram, and not other inhibitors selective for PDE isozymes,Fig. 4. Eﬀects of PDE isozyme selective inhibitors on osteoclast
formation and TRANCE mRNA expression in calvarial osteoblasts.
(A and B) Mouse bone marrow cells and calvarial osteoblasts were
cocultured in the absence or presence of vinpocetine (30 lM), EHNA
(10 lM), milrinone (10 lM), rolipram (10 lM), dipyridamole (30 lM),
zaprinast (100 lM) (selective inhibitors for PDE1, 2, 3, 4, 5 and 8, 5
and 9, respectively), pentoxifylline (200 lM), or IBMX (50 lM) (non-
selective inhibitors) for 6 days (A). Mouse bone marrow cells and
calvarial osteoblasts were cocultured with indicated concentrations of
rolipram for 6 days (B). Cells were then ﬁxed and stained for TRAP.
Data are expressed as means + S.D. of triplicate cultures. (C) Calvarial
osteoblasts were treated with vinpocetine, EHNA, milrinone, rolipram,
dipyridamole, zaprinast, or IBMX for 3 h. Expressions of TRANCE
and GAPDH mRNA were determined by RT-PCR. (D) Calvarial
osteoblasts were preincubated in the absence () or presence (+) of
30 lM of H89, 50 lM of PD98059, or 50 lM of SB203580 for 30 min,
and then treated with (+) or without () 10 lM of rolipram for 3 h.
Total RNA was extracted from the cells and the expressions of
TRANCE and GAPDH mRNA were examined by Northern-blot
analysis.
b
Fig. 5. Characterization of calvarial osteoblasts and the stromal cell
line in expression patterns of PDE4 subtypes, osteoclastogenesis-
supporting ability, and TRANCE mRNA expression in response to
IBMX and 1,25(OH)2D3. (A) Total RNA was extracted from mouse
calvarial cells or UAMS-32 cells. The expression of PDE4 subtype
(PDE4A-D) mRNA was analyzed by RT-PCR. (B) Mouse bone
marrow cells were cocultured with calvarial osteoblasts or UAMS-32
cells in the absence () or presence (+) of 1,25(OH)2D3 (10 nM) or
IBMX (50 lM) for 6 days. Cells were then ﬁxed and stained for TRAP.
Data are expressed as means + S.D. of triplicate cultures. (C) Calvarial
osteoblasts or UAMS-32 cells were treated with (+) or without ()
1,25(OH)2D3 (10 nM) or IBMX (50 lM) for 3 h. Total RNA was then
extracted from the cells, and the expressions of TRANCE and
GAPDH mRNA were determined by RT-PCR.
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sion in calvarial osteoblasts. These results suggest that PDE4
is a key functional enzyme in the regulation of cAMP-medi-
ated TRANCE expression in mouse calvarial osteoblasts.
Additionally, it has been reported that selective inhibitors for
PDE4 enhanced the diﬀerentiation of osteogenic precursor
cells with stimulation by bone morphogenetic protein-4
(BMP-4) [21]. Thus, PDE4 in osteoblasts is a key regulator
for both osteoclast- and osteoblast diﬀerentiation.
In conclusion, PDE inhibitors promote osteoclast formation
via TRANCE expression in osteoblasts. TRANCE expression
induced by PDE inhibitors is possibly mediated by ERK and
p38 MAPK, as well as PKA activation. Further analysis ofanimals given PDE inhibitors will contribute to the develop-
ment of anti-osteoporosis drugs based on PDE activities.
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